Influence of P53 on the radiotherapy response of hepatocellular carcinoma

• Main Authors: Ana R. Gomes, Ana M. Abrantes, Ana F. Brito, Mafalda Laranjo, João E. Casalta-Lopes, Ana C. Gonçalves, Ana B. Sarmento-Ribeiro, Maria F. Botelho, José G. Tralhão
• Format: Article
• Language: English
• Published: Korean Association for the Study of the Liver 2015-09-01
• Series: Clinical and Molecular Hepatology
• Subjects: Hepatocellular carcinoma; Iodine-131; Radiotherapy; P53
• Online Access: http://e-cmh.org/upload/pdf/cmh-21-257.pdf

Background/AimsHepatocellular carcinoma (HCC) is one of the most common cancers worldwide, and it has a poor prognosis and few therapeutic options. Radiotherapy is one of the most effective forms of cancer treatment, and P53 protein is one of the key molecules determining how a cell responds to radiotherapy. The aim of this study was to determine the therapeutic efficacy of iodine-131 in three human HCC cell lines.MethodsWestern blotting was used to measure P53 expression. The effects of radiotherapy with iodine-131 were assessed by using the clonogenic assay to evaluate cell survival. Flow cytometry was carried out to examine the effects of iodine-131 on cell death, oxidative stress, reduced intracellular glutathione expression, the mitochondrial membrane potential, and the cell cycle.ResultsThe P53 protein was not expressed in Hep3B2.1-7 cells, was expressed at normal levels in HepG2 cells, and was overexpressed in HuH7 cells. P53 expression in the HuH7 and HepG2 cell lines increased after internal and external irradiation with iodine-131. Irradiation induced a decrease in cell survival and led to a decrease in cell viability in all of the cell lines studied, accompanied by cell death via late apoptosis/necrosis and necrosis. Irradiation with 131-iodine induced mostly cell-cycle arrest in the G0/G1 phase.ConclusionsThese results suggest that P53 plays a key role in the radiotherapy response of HCC.